Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 30;15(13):3450.
doi: 10.3390/cancers15133450.

Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence

Audrey Michot  1   2   3 , Pauline Lagarde  2   3 , Tom Lesluyes  2 , Elodie Darbo  1   3 , Agnès Neuville  2 , Jessica Baud  1 , Gaëlle Perot  4   5 , Iris Bonomo  2 , Mathilde Maire  2 , Maxime Michot  2 , Jean-Michel Coindre  2   3 , François Le Loarer  1   2   3 , Frédéric Chibon  4   5
Affiliations

Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence

Audrey Michot et al. Cancers (Basel). .

Abstract

Background: The management of soft-tissue sarcoma (STS) relies on a multidisciplinary approach involving specialized oncological surgery combined with other adjuvant therapies to achieve optimal local disease control. Purpose and Results: Genomic and transcriptomic pseudocapsules of 20 prospective sarcomas were analyzed and revealed to be correlated with a higher risk of recurrence after surgery.

Conclusions: A peritumoral environment that has been remodeled and infiltrated by M2 macrophages, and is less expressive of healthy tissue, would pose a significant risk of relapse and require more aggressive treatment strategies.

Keywords: molecular changes; peritumoral capsule; peritumoral tissue; recurrence; soft-tissue sarcoma.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Pathological changes observed by HE staining from HT to R1 to T. (Case 5 and 14, respectively).
Figure 2
Figure 2
Genomic profiles obtained via CGH on three areas: T tumor, R1 non-tumoral surrounding tissue, and HT healthy tissue at distance. Tumor genome was highly rearranged, while R1 and HT were flat.
Figure 3
Figure 3
Unsupervised non-hierarchical paired clustering with all probes of all entities for all samples. Three groups are designed according to their expression differential.
Figure 4
Figure 4
Difference in the expression of the gene MYOM2 from GO:0003012 in our four groups (HT, R1.h, R1.t, and T).
Figure 5
Figure 5
(A): Normal striated muscle; (B): Rearranged fibroadipose tissue.
Figure 6
Figure 6
Kaplan–Meier curve of overall survival. R1.h in blue; R1.t in red.
Figure 7
Figure 7
Kaplan–Meier curve for probability of local or metastatic recurrence. R1.h in blue; R1.t in red.
Figure 8
Figure 8
CIBERSORT method: signature of an immune infiltrate of each sample. It was reported the differential expression of immune cells of macrophages M2, macrophages M0, monocytes, mast cells resting, B cells memory, T cells CD4 naïve, neutrophils, T cells follicular helper, macrophages M1, T regulators, Natural killer cells resting, T cells CD4 memory activated, dendritic cells resting, dendritic cells activated, T cells gamma delta, B cells naïve, eosinophils, mast cells activated, T cells CD4 memory resting, T cells CD8, NK cells activated in each area of samples.
Figure 9
Figure 9
(A): Patient #9: numerous cells showing a double marquage for CD-68 and c-MAF highlighting the presence of M2 macrophages. This patient died with metastases 25 months after the diagnosis. (B): Patient #18: simple marquage for CD-68 with no M2 cells. This patient is in complete remission 44 months after diagnosis.
See this image and copyright information in PMC

References

    1. Stiller C.A., Trama A., Serraino D., Rossi S., Navarro C., Chirlaque M.D., Casali P.G., RARECARE Working Group Descriptive Epidemiology of Sarcomas in Europe: Report from the RARECARE Project. Eur. J. Cancer. 2013;49:684–695. doi: 10.1016/j.ejca.2012.09.011. - DOI - PubMed
    1. Penel N., Coindre J.-M., Giraud A., Terrier P., Ranchere-Vince D., Collin F., Guellec S.L.E., Bazille C., Lae M., de Pinieux G., et al. Presentation and Outcome of Frequent and Rare Sarcoma Histologic Subtypes: A Study of 10,262 Patients with Localized Visceral/Soft Tissue Sarcoma Managed in Reference Centers. Cancer. 2018;124:1179–1187. doi: 10.1002/cncr.31176. - DOI - PubMed
    1. Stoeckle E., Coindre J.-M., Kind M., Kantor G., Bui B.N. Evaluating Surgery Quality in Soft Tissue Sarcoma. Recent Results Cancer Res. 2009;179:229–242. doi: 10.1007/978-3-540-77960-5_14. - DOI - PubMed
    1. Gronchi A., Palmerini E., Quagliuolo V., Martin Broto J., Lopez Pousa A., Grignani G., Brunello A., Blay J.-Y., Tendero O., Diaz Beveridge R., et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. J. Clin. Oncol. 2020;38:2178–2186. doi: 10.1200/JCO.19.03289. - DOI - PubMed
    1. Chibon F., Lagarde P., Salas S., Pérot G., Brouste V., Tirode F., Lucchesi C., de Reynies A., Kauffmann A., Bui B., et al. Validated Prediction of Clinical Outcome in Sarcomas and Multiple Types of Cancer on the Basis of a Gene Expression Signature Related to Genome Complexity. Nat. Med. 2010;16:781–787. doi: 10.1038/nm.2174. - DOI - PubMed